The Phase III METEOROID study met its primary endpoint, with ENSPRYNG cutting the risk of a first relapse by 68% compared to placebo in adults and adolescents
The decision marks a pivotal moment for the Massachusetts-based biotech giant
Investment marks continued progress against AbbVie's $100 billion commitment to U.S. R&D and capital investments, including manufacturing, over the next decade
If approved, DTX401 would be the first treatment to address the disease at its root cause
The collaboration aims to combine synthetic biology with cutting-edge detection technology to create a first-of-its-kind oral pill embedded with tumor-targeting sensors
The FDA setback highlights ongoing tensions between patient needs, regulatory processes, and the use of real-world evidence in evaluating treatments for rare diseases
The expansion will significantly enhance AbbVie’s ability to meet growing global demand for biologics, particularly in oncology and immunology
Rhonda Pacheco to succeed Julie Kim, who was appointed to be Takeda’s next CEO
He has successfully led the development of 15 approved drugs worldwide across various therapeutic areas over his more than 20-year career
Merck and mantro GmbH have established EdiMembre, Massachusetts, U.S.A., a Deep Tech spin-out in the alternative protein industry
Subscribe To Our Newsletter & Stay Updated
